We applied PF-04217903, a selective MET signaling inhibitor, in the hepa1-6 orthotopic models, and found that PF-04217903 alone did not result in obvious alterations in tumor volume and metastasis compared with the controls (Fig. 3a). Here, MET is linked to neoplasm.